Matthew Capehorn

1.7k total citations · 2 hit papers
35 papers, 1.2k citations indexed

About

Matthew Capehorn is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and General Health Professions. According to data from OpenAlex, Matthew Capehorn has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 6 papers in General Health Professions. Recurrent topics in Matthew Capehorn's work include Diabetes Treatment and Management (19 papers), Metabolism, Diabetes, and Cancer (14 papers) and Diabetes Management and Research (7 papers). Matthew Capehorn is often cited by papers focused on Diabetes Treatment and Management (19 papers), Metabolism, Diabetes, and Cancer (14 papers) and Diabetes Management and Research (7 papers). Matthew Capehorn collaborates with scholars based in United Kingdom, Denmark and United States. Matthew Capehorn's co-authors include Anders G. Holst, Ildiko Lingvay, Vanita R. Aroda, G. Charpentier, Andrew Ahmann, Miriam Annett, Elena Henkel, Francesco Dotta, Andrei‐Mircea Catarig and Andrej Janež and has published in prestigious journals such as Journal of the American College of Cardiology, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

In The Last Decade

Matthew Capehorn

33 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

2017 438 citations Andrew Ahmann, Matthew Capehorn et al. profile →
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

2019 283 citations Matthew Capehorn, Andrei‐Mircea Catarig et al. Diabetes & Metabolism profile →

Peers

Countries citing papers authored by Matthew Capehorn

Since Specialization

Citations

This map shows the geographic impact of Matthew Capehorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Capehorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Capehorn more than expected).

Fields of papers citing papers by Matthew Capehorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Capehorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Capehorn. The network helps show where Matthew Capehorn may publish in the future.

Co-authorship network of co-authors of Matthew Capehorn

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Capehorn. A scholar is included among the top collaborators of Matthew Capehorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Capehorn. Matthew Capehorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	EE789 Cost-Effectiveness of Tirzepatide Versus Liraglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective 2024 ·Value in Health ·Matthew Capehorn, Elin Johansson, (unknown), J. G. Evans, (unknown), (unknown), (unknown), Keith Tolley	1
2	EE287 Cost-Effectiveness of Tirzepatide As an Adjunct to a Reduced-Calorie Diet and Increased Physical Activity Versus Diet and Exercise Alone in Patients With Obesity or Overweight From a UK Perspective 2024 ·Value in Health ·Matthew Capehorn, (unknown), Elin Johansson, J Brière, (unknown), J. G. Evans, (unknown), (unknown), (unknown), Keith Tolley	1
3	EE117 Cost-Effectiveness of Tirzepatide Versus Semaglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective 2024 ·Value in Health ·Matthew Capehorn, Elin Johansson, (unknown), J. G. Evans, (unknown), (unknown), (unknown), Keith Tolley	2
4	Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China 2023 ·Diabetes Obesity and Metabolism ·Linong Ji, Andrew Ahmann, Bo Åhrén, Matthew Capehorn, Ping Hu, Ildiko Lingvay, Wenjun Liu, Helena W. Rodbard, Zhufang Shen, Christopher Sorli	3
5	Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials 2022 ·Cardiovascular Diabetology ·Ofri Mosenzon, Matthew Capehorn, Alessandra De Remigis, Søren Rasmussen, Petra Weimers, Julio Rosenstock	43
6	The Potential Role of Digital Health in Obesity Care 2022 ·Advances in Therapy ·(unknown), Matthew Capehorn, M. Bewick, (unknown)	39
7	Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering Committee 2022 ·Advances in Therapy ·Matthew Capehorn, (unknown), (unknown), Andrew J. Hill, (unknown), Abd A. Tahrani, Ann Vincent, Simon Williams, (unknown)	7
8	Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting 2021 ·Diabetes Therapy ·Matthew Capehorn, (unknown), (unknown), (unknown), Barnaby Hunt	22
9	SEMAGLUTIDE REDUCES HIGH-SENSITIVITY CRP LEVELS ACROSS DIFFERENT TREATMENT FORMULATIONS: EXPLORATORY ANALYSES OF SUSTAIN 3 AND PIONEER 1, 2 AND 5 TRIALS 2021 ·Journal of the American College of Cardiology ·Julio Rosenstock, Matthew Capehorn, Alessandra De Remigis, Søren Rasmussen, Petra Weimers, Ofri Mosenzon	5
10	Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK 2020 ·Advances in Therapy ·Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J. P. Malkin, Anna Sandberg, Matthew Capehorn	19
11	Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10 2020 ·Diabetes Therapy ·Matthew Capehorn, (unknown), Charlotte Hindsberger, Pierre Johansen, Esteban Jódar	10
12	PDB25 The Cost-Effectiveness of ORAL Semaglutide in Patients Treated with Currently Available GLP-1 Receptor Agonists - a UK Perspective 2020 ·Value in Health ·Barrie Chubb, (unknown), Matthew Capehorn	1
13	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme 2019 ·Diabetes Therapy ·Stephen C. Bain, Brian Bekker Hansen, Samuel J. P. Malkin, (unknown), William J. Valentine, Barrie Chubb, Barnaby Hunt, Matthew Capehorn	45
14	Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) breakdown → 2019 ·Diabetes & Metabolism ·Matthew Capehorn, Andrei‐Mircea Catarig, (unknown), Andrej Janež, Hermione Price, (unknown), Bruno Vergès, Michel Marre	283
15	Physician–patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes – New findings from the global IntroDia® study 2019 ·Diabetes Research and Clinical Practice ·Steven V. Edelman, Anne Belton, (unknown), Aus Alzaid, Matthew Capehorn, Victoria Gamerman, (unknown), Jisoo Lee, (unknown), William H. Polonsky	14
16	Efficacy of an intermittent energy restriction diet in a primary care setting 2019 ·European Journal of Nutrition ·Rona Antoni, Kelly L. Johnston, (unknown), (unknown), M. Denise Robertson, Matthew Capehorn	13
17	Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® study 2019 ·Diabetes Research and Clinical Practice ·(unknown), Aus Alzaid, William H. Polonsky, Anne Belton, Steven V. Edelman, Victoria Gamerman, (unknown), Jisoo Lee, (unknown), Matthew Capehorn	4
18	Physician–patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® study 2017 ·Diabetes Research and Clinical Practice ·William H. Polonsky, Matthew Capehorn, Anne Belton, (unknown), Aus Alzaid, Victoria Gamerman, (unknown), Jisoo Lee, Steven V. Edelman	41
19	Obesity Treatment in the UK Health System 2016 ·Current Obesity Reports ·Matthew Capehorn, David W. Haslam, Richard Welbourn	24
20	Public health. Catching up with the obesity crisis. 2013 ·PubMed ·Matthew Capehorn	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact